original ) (raw )The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D 4.4 receptor
Bernd Sommer
British Journal of Pharmacology, 1998
View PDFchevron_right
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15
Zsolt Némethy
View PDFchevron_right
Response : Elevated D 2 Dopamine Receptors in Drug-Naïve Schizophrenics
Albert Gjedde
Science, 1988
View PDFchevron_right
Half a century of antipsychotics and still a central role for dopamine D2 receptors
David Mamo
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
View PDFchevron_right
Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907
Durk Dijkstra
European Journal of Pharmacology, 1998
View PDFchevron_right
Elevated D2 dopamine receptors in drug-naive schizophrenics
Albert Gjedde
Science, 1988
View PDFchevron_right
Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat
Patricia Jimenez
European Neuropsychopharmacology, 1996
View PDFchevron_right
History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia
Bertha Madras
Http Dx Doi Org 10 1080 0964704x 2012 678199, 2013
View PDFchevron_right
Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists
Raymond Suckow
Neuropsychopharmacology, 2003
View PDFchevron_right
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A
R GG
Proceedings of the National Academy of Sciences
View PDFchevron_right
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Dr. István Laszlovszky
Journal of Pharmacology and Experimental Therapeutics, 2010
View PDFchevron_right
Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors
Robert McQuade
European Journal of Pharmacology, 2011
View PDFchevron_right
Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride
Jogeshwar Mukherjee , Bradley Christian
Neuropsychopharmacology, 2001
View PDFchevron_right
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
Béla Kiss
Naunyn-Schmiedeberg's Archives of Pharmacology, 2008
View PDFchevron_right
Dopaminergic stabilizers for the treatment of schizophrenia. Rat studies focusing on negative symptoms and mechanisms of action
Johan Rung
View PDFchevron_right
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents
Richard Mailman
European Journal of Pharmacology, 1993
View PDFchevron_right
Dopamine D 2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D 2 receptor signaling
Shaun Jordan
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2007
View PDFchevron_right
Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects
Alexandra Soliman
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001
View PDFchevron_right
Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol
Linda Peacock
European Journal of Pharmacology, 1993
View PDFchevron_right
Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice
Dubravka Hranilovic
Molecular Psychiatry, 2002
View PDFchevron_right
Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors : Common targets for typical and atypical antipsychotic drugs
Ross Baldessarini
Progress in Neuro Psychopharmacology Biological Psychiatry, 1998
View PDFchevron_right
Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: Common targets for typical and atypical antepsychotic drugs
John Neumeyer
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998
View PDFchevron_right
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
T. Cooper , M. Laruelle , Lawrence Kegeles
Proceedings of the National Academy of Sciences, 2000
View PDFchevron_right
Occupancy of dopamine D 2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications
M. Laruelle
…, 2004
View PDFchevron_right
F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
Ronan Depoortere , Adrian Newman-Tancredi , Agnès Auclair
Naunyn-Schmiedeberg's Archives of Pharmacology, 2007
View PDFchevron_right
Selectivity of agonists and antagonists at D2dopamine receptors compared to D1 and S2receptors
Dimitri Grigoriadis
Drug Development Research, 1986
View PDFchevron_right
The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors
Kjell Fuxe
Neuroscience, 1994
View PDFchevron_right
Long-Term Effects of S(+)N-n-Propylnorapomorphine Compared with Typical and Atypical Antipsychotics: Differential Increases of Cerebrocortical D2-Like and Striatolimbic D4-Like Dopamine Receptors
Ross Baldessarini
Neuropsychopharmacology, 1997
View PDFchevron_right